These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 10931582)

  • 1. Safety of approved MR contrast media for intravenous injection.
    Runge VM
    J Magn Reson Imaging; 2000 Aug; 12(2):205-13. PubMed ID: 10931582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of magnetic resonance contrast media.
    Runge VM
    Top Magn Reson Imaging; 2001 Aug; 12(4):309-14. PubMed ID: 11687717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging.
    Kim SK; Kim SH; Lee WJ; Kim H; Seo JW; Choi D; Lim HK; Lee SJ; Lim JH
    AJR Am J Roentgenol; 2002 Sep; 179(3):741-50. PubMed ID: 12185056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast agents for magnetic resonance imaging: safety update.
    Kirchin MA; Runge VM
    Top Magn Reson Imaging; 2003 Oct; 14(5):426-35. PubMed ID: 14625469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-enhanced MR imaging of the liver.
    Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
    J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings.
    Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR
    Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contrast agents in MRT. Substance, effects, pharmacology and validity].
    Reimer P; Vosshenrich R
    Radiologe; 2004 Mar; 44(3):273-83. PubMed ID: 15287365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
    Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
    AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
    J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of MR contrast agents for evaluating liver disease.
    Ward J; Robinson PJ
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of MR liver specific contrast media.
    Bellin MF; Webb JA; Van Der Molen AJ; Thomsen HS; Morcos SK;
    Eur Radiol; 2005 Aug; 15(8):1607-14. PubMed ID: 15627176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse reaction to intravenous gadoteridol.
    Shellock FG; Hahn HP; Mink JH; Itskovich E
    Radiology; 1993 Oct; 189(1):151-2. PubMed ID: 8372186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol.
    Bluemke DA; Weber TM; Rubin D; de Lange EE; Semelka R; Redvanly RD; Chezmar J; Outwater E; Carlos R; Saini S; Holland GA; Mammone JF; Brown JJ; Milestone B; Javitt MC; Jacobs P
    Radiology; 2003 Aug; 228(2):457-64. PubMed ID: 12893904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 mumol/kg body weight in detecting focal liver tumors: results of a phase III trial using an infusion technique.
    Padovani B; Lecesne R; Raffaelli C; Chevallier P; Drouillard J; Bruneton JN; Lambrechts M; Gordon P
    Eur J Radiol; 1996 Nov; 23(3):205-11. PubMed ID: 9003926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver-specific MR imaging contrast agents.
    Hahn PF; Saini S
    Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of liver contrast agents: impact for clinical use.
    Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
    Tweedle MF; Wedeking P; Kumar K
    Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current status of the clinical development of MR contrast media].
    Laniado M; Kopp AF
    Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients.
    Kim HJ; Kim KW; Byun JH; Won HJ; Shin YM; Kim PN; Lee MS; Lee MG
    AJR Am J Roentgenol; 2006 Apr; 186(4):1059-66. PubMed ID: 16554579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.